Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
Why Rare Disease Commercial Strategy Should Begin Before Phase III
Rare disease commercial strategy should begin before Phase III. Learn how patient identification, Centers of Excellence, evidence and capital allocation shape commercialization.
Read ArticleRare Disease Market Access: Building the Evidence Before Launch
Rare disease market access begins before launch. Learn how clinical development, HEOR, payer evidence and treatment sequencing can shape reimbursement and commercial value.
Read ArticleCommercial Strategy Before Phase 3: Connecting Clinical Development to Commercial Value
Phase 3 decisions shape more than regulatory approval. Learn how clinical development, differentiation, payer evidence and capital allocation determine future commercial value.
Read ArticleNeurology Drug Commercialization: Differentiation Beyond Clinical Trial Success
Neurology drug commercialization requires more than positive trial results. Learn how patient selection, treatment pathways and meaningful differentiation can shape commercial value.
Read ArticleRare Disease Commercialization: Why the Treatable Patient Population Matters More Than Prevalence
Rare disease prevalence can overstate commercial opportunity. Learn why reachable patients, treatment pathways, clinical evidence and reimbursement should shape commercialization strategy.
Read ArticleBuilding the First Commercial Organization in Biotech
How should an emerging biotech build its first commercial organization? Explore leadership, sequencing, build-versus-outsource decisions, capabilities and common mistakes.
Read ArticleBiotech Commercial Readiness: What Should Be in Place Before Phase III?
What should an emerging biotechnology company understand before Phase III? A commercial readiness perspective covering market, access, evidence, organization and strategic decisions.
Read ArticleAlzheimer’s Disease: Are We Still Looking for One Answer to a Multi-Process Disease?
After decades of Alzheimer’s research, failed trials, approved anti-amyloid therapies, a broader pipeline and AI raise a strategic question: can we better identify which biology matters in which patient—and make better scientific, clinical and investment decisions as a result?
Read Article